Mechanisms and reversal strategies of tumor multidrug resistance

doi:10.3760/cma.j.issn.1673-422X.2013.12.003

Abstract

Abstract: Tumor multidrug resistance (MDR) is the leading cause of clinical chemotherapy failure and death. Researches show that the occurrence of MDR is related to Pglycoprotein, multidrug resistanceassociated proteins, breast cancer resistanceassociated proteins, lung resistancerelated proteins and other factors. Now the reversal strategies of MDR include chemical drugs reversal, gene reversal, immune reversal, traditional Chinese medicine reversal and drugloaded nanosystem reversal, which make some progress and help to improve the effect of cancer chemotherapy.

Key words: Neoplasms, Drug resistance, multiple, Nanotechnology

WU Jing, YANG Rui, LIU Shu-Ye. Mechanisms and reversal strategies of tumor multidrug resistance[J]. Journal of International Oncology, 2013, 40(12): 889-892.

References

［1］ Wang XB, Wang SS, Zhang QF, et al. Inhibition of tetramethylpyrazine on Pgp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep, 2010, 23(1): 211215. ［2］ Zhao L, Jin X, Xu Y, et al. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene1. J Exp Clin Cancer Res, 2010, 29(1): 98. ［3］ Wang YL, Yan YL, Zhou NJ, et al. Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP. Chin Med J (Engl), 2010, 123(22): 32993303. ［4］ Lechler P, Renkawitz T, Campean V, et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer, 2011, 11: 120. ［5］ Li H, Hui L, Xu W, et al. Modulation of Pglycoprotein expression by triptolide in adriamycinresistant K562/A02 cells. Oncol Lett, 2012, 3(2): 485489. ［6］ Zhang H, Jiang H, Wang X, et al. Reversion of multidrug resistance in tumor by biocompatible nanomaterials. Mini Rev Med Chem, 2010, 10(8): 737745. ［7］ Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATPbinding cassette transporters. Cancer Res, 2010, 70(20): 79817991. ［8］ Imai Y, Yoshimori M, Fukuda K, et al. The PI3K/Akt inhibitor LY294002 reverses BCRPmediated drug resistance without affecting BCRP translocation. Oncol Rep, 2012, 27(6): 17031709. ［9］ Xing AY, Shi DB, Liu W, et al. Restoration of chemosensitivity in cancer cells with MDR phenotype by deoxyribozyme, compared with ribozyme. Exp Mol Pathol, 2013, 94(3): 481485. ［10］ Shi R, Peng H, Yuan X, et al. Downregulation of cfos by shRNA sensitizes adriamycinresistant MCF7/ADR cells to chemotherapeutic agents via Pglycoprotein inhibition and apoptosis augmentation. J Cell Biochem, 2013, 114(8): 18901900. ［11］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line. DNA Cell Biol, 2011, 30(6): 413418. ［12］ Kim DY, Kim MJ, Kim HB, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of cMyc. Biochim Biophys Acta, 2011, 1812(7): 796805. ［13］ Lu JJ, Cai YJ, Ding J. The shorttime treatment with curcumin sufficiently decreases cells viability, induces apoptosis and copper enhances these effects in multidrugresistant K562/A02 cells. Mol Cell Biochem, 2012, 360(12): 253260. ［14］ Cao SQ, Yin TY, Yang SL. Reversing effects of curcumin on multidrug resistance of Bel7402/5fu cell line. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32(2): 244247, 252. ［15］ Li SZ, Li K, Zhang JH, et al. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. Anticancer Agents Med Chem, 2013, 13(2): 352355. ［16］ Yuan J, Wong IL, Jiang T, et al. Synthesis of methylated quercetin derivatives and their reversal activities on Pgp and BCRPmediated multidrug resistance tumour cells. Eur J Med Chem, 2012, 54: 413422. ［17］ Lei Y, Tan J, Wink M, et al. An isoquinoline alkaloid from the Chinese herbal plant Corydalis yanhusuo W.T. Wang inhibits Pglycoprotein and multidrug resistanceassociate protein 1. Food Chem, 2013, 136(34): 11171121. ［18］ Luo SX, Deng WY, Wang XF, et al. Molecular mechanism of indirubin3′monoxime and Matrine in the reversal of paclitaxel resistance in NCIH520/TAX25 cell line. Chin Med J (Engl), 2013, 126(5): 925929. ［19］ Chen G, Wang K, Yang BY, et al. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol, 2012, 40(1): 139147. ［20］ Kobayashi E, Lyer AK, Hornicek FJ, et al. Lipidfunctionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res, 2013, 471(3): 915925. ［21］ Zhang Z, Liu Z, Ma L, et al. Reversal of multidrug resistance by mitochondrial targeted selfassembled nanocarrier based on stearylamine. Mol Pharm, 2013, 10(6): 24262434. ［22］ Dreaden EC, Austin LA, Mackey MA, et al. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv, 2012, 3(4): 457478. ［23］ Zhi F, Dong H, Jia X, et al. Functionalized grapheme oxide mediated adriamycin delivery and miR21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS One, 2013, 8(3): e60034. ［24］ Ren F, Chen R, Wang Y, et al. Paclitaxelloaded poly(nbutylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Pharm Res, 2011, 28(4): 897906. ［25］ Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by coencapsulation of doxorubicin and curcumin in chitosan/poly (butylcyanoacrylate) nanoparticles. Int J Pharm, 2012, 426(12): 193201. ［26］ Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release, 2010, 148(2): 135146. ［27］ Huang IP, Sun SP, Cheng SH, et al. Enhanced chemotherapy of cancer using pHsensitive mesoporous silica nanoparticles to antagonize Pglycoproteinmediated drug resistance. Mol Cancer Ther, 2011, 10(5): 761769. ［28］ Gao ZG, Tian L, Hu J, et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J Control Release, 2011, 152(1): 8489.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.